Kaster Tyler S, Campitelli Michael A, Babujee Amreen, Huang Anjie, Ladha Karim, Blumberger Daniel M, Kurdyak Paul
Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.
Can J Psychiatry. 2025 Aug 28:7067437251371977. doi: 10.1177/07067437251371977.
Electroconvulsive therapy (ECT) is an important but underused treatment for severe psychiatric illnesses. We sought to examine the variability of ECT utilization at a population level and between several subgroups. We also sought to quantify the impact of the COVID-19 pandemic on ECT utilization.
We used population level data from Ontario to examine all ECT procedures administered from 1 January 2007 to 31 December 2023. Our primary measure of variability was the rate of ECT procedures per 1,000 population. We included three subgroups at time of ECT procedure: age (18-39, 40-64, and 65+), biologic sex (male/female), and Ontario Health (OH) region of residence (West, Central, Toronto, East, North West, North East). To quantify the impact of the COVID-19 pandemic we calculated the change in ECT rate from 2019 to 2020 (acute effect) and 2019 to 2023 (persistent effect).
There were 450,381 ECT procedures delivered during the observation period. The yearly rate of ECT increased from 1.69 per 1,000 in 2007 to a peak of 3.08 per 1,000 in 2019. In 2023 the greatest per capita rates of ECT use were in the 65+ age group, female sex, and North East geographic region. In 2023, the rates of ECT use in different geographic regions ranged from 1.28 (North West) to 4.19 per 1,000 (North East). The COVID-19 pandemic resulted in an immediate 26.73%, followed by a 17.47% persistent drop in the rate of ECT with notable regional heterogeneity.
While ECT use increased over time, there were differences in this increase between age groups, biological sex, and geographic regions. The COVID-19 pandemic had significant immediate and persistent impacts on the rates of ECT use highlighting the need for ongoing population level monitoring of this important treatment.
电休克疗法(ECT)是治疗严重精神疾病的一种重要但未得到充分利用的疗法。我们试图研究ECT在人群层面以及几个亚组之间使用情况的变异性。我们还试图量化2019冠状病毒病大流行对ECT使用的影响。
我们使用安大略省的人群层面数据,研究2007年1月1日至2023年12月31日期间实施的所有ECT治疗。我们衡量变异性的主要指标是每1000人口的ECT治疗率。我们纳入了ECT治疗时的三个亚组:年龄(18 - 39岁、40 - 64岁和65岁及以上)、生物学性别(男性/女性)以及居住的安大略省卫生(OH)区域(西部、中部、多伦多、东部、西北、东北)。为了量化2019冠状病毒病大流行的影响,我们计算了2019年至2020年(急性效应)以及2019年至2023年(持续效应)ECT治疗率的变化。
在观察期内共进行了450,381次ECT治疗。ECT的年治疗率从2007年的每1000人1.69次增加到2019年的峰值每1000人3.08次。2023年,ECT人均使用率最高的是65岁及以上年龄组、女性以及东北地区。2023年,不同地理区域的ECT使用率从每1000人1.28次(西北)到4.19次(东北)不等。2019冠状病毒病大流行导致ECT治疗率立即下降26.73%,随后持续下降17.47%,且存在显著的区域异质性。
虽然ECT的使用随时间增加,但在年龄组、生物学性别和地理区域之间,这种增加存在差异。2019冠状病毒病大流行对ECT的使用率产生了重大的即时和持续影响,凸显了对这种重要治疗方法进行持续人群层面监测的必要性。